Survival in gastric and esophageal cancers in the Nordic countries through a half century.
mortality
relative survival
risk factors
stomach cancer
treatment
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
08
01
2023
received:
29
05
2022
accepted:
16
02
2023
medline:
30
5
2023
pubmed:
28
2
2023
entrez:
27
2
2023
Statut:
ppublish
Résumé
Gastric cancer (GC) and esophageal cancer (EC) are among the most fatal cancers and improving survival in them is a major clinical challenge. Nordic cancer data were recently released up to year 2019. These data are relevant for long-term survival analysis as they originate from high-quality national cancer registries from countries with practically free access to health care, thus documenting 'real-world' experience for entire populations. Data were obtained for Danish (DK), Finnish (FI), Norwegian (NO), and Swedish (SE) patients from the NORDCAN database from years 1970 through 2019. Relative 1- and 5-year survival were analyzed, and additionally the difference between 1- and 5-year survival was calculated as a measure of trends between years 1 and 5 after diagnosis. Relative 1-year survival for Nordic men and women in GC was 30% in period 1970-74 and it increased close to 60%. Early 5-year survival ranged between 10 and 15% and the last figures were over 30% for all women and NO men while survival for other men remain below 30%. Survival in EC was below that in GC, and it reached over 50% for 1-year survival only for NO patients; 5-year survival reached over 20% only for NO women. For both cancers, the difference between 1- and 5-year survival increased with time. Survival was worst among old patients. GC and EC survival improved over the 50-year period but the increase in 5-year survival was entirely explained by gains in 1-year survival, which improved at an accelerated pace in EC. The likely reasons for improvements are changes in diagnosis, treatment, and care. The challenges are to push survival past year 1 with attention to old patients. These cancers have a potential for primary prevention through the avoidance of risk factors.
Sections du résumé
BACKGROUND
Gastric cancer (GC) and esophageal cancer (EC) are among the most fatal cancers and improving survival in them is a major clinical challenge. Nordic cancer data were recently released up to year 2019. These data are relevant for long-term survival analysis as they originate from high-quality national cancer registries from countries with practically free access to health care, thus documenting 'real-world' experience for entire populations.
PATIENTS/METHODS
Data were obtained for Danish (DK), Finnish (FI), Norwegian (NO), and Swedish (SE) patients from the NORDCAN database from years 1970 through 2019. Relative 1- and 5-year survival were analyzed, and additionally the difference between 1- and 5-year survival was calculated as a measure of trends between years 1 and 5 after diagnosis.
RESULTS
Relative 1-year survival for Nordic men and women in GC was 30% in period 1970-74 and it increased close to 60%. Early 5-year survival ranged between 10 and 15% and the last figures were over 30% for all women and NO men while survival for other men remain below 30%. Survival in EC was below that in GC, and it reached over 50% for 1-year survival only for NO patients; 5-year survival reached over 20% only for NO women. For both cancers, the difference between 1- and 5-year survival increased with time. Survival was worst among old patients.
CONCLUSION
GC and EC survival improved over the 50-year period but the increase in 5-year survival was entirely explained by gains in 1-year survival, which improved at an accelerated pace in EC. The likely reasons for improvements are changes in diagnosis, treatment, and care. The challenges are to push survival past year 1 with attention to old patients. These cancers have a potential for primary prevention through the avoidance of risk factors.
Identifiants
pubmed: 36846972
doi: 10.1002/cam4.5748
pmc: PMC10225220
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10212-10221Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Health Policy. 2012 Apr;105(1):65-70
pubmed: 22136810
Cancer Med. 2023 May;12(9):10212-10221
pubmed: 36846972
Cancer Med. 2018 Nov;7(11):5534-5542
pubmed: 30328287
Lancet Oncol. 2019 Nov;20(11):1493-1505
pubmed: 31521509
Eur J Cancer Prev. 2022 May 1;31(3):228-234
pubmed: 34074862
Acta Oncol. 2018 Apr;57(4):440-455
pubmed: 29226751
Eur J Cancer. 2022 Nov;175:77-85
pubmed: 36096040
Gastroenterology. 2020 Jul;159(1):335-349.e15
pubmed: 32247694
Lancet. 2020 Aug 29;396(10251):635-648
pubmed: 32861308
JAMA. 2020 Dec 22;324(24):2536-2547
pubmed: 33351048
Eur J Cancer. 2022 Sep;172:76-84
pubmed: 35759813
Lancet. 2021 Jul 3;398(10294):27-40
pubmed: 34102137
Gut. 2022 Aug;71(8):1532-1543
pubmed: 34824149
PLoS One. 2021 Jun 22;16(6):e0253236
pubmed: 34157049
Cancers (Basel). 2021 Aug 30;13(17):
pubmed: 34503195
Int J Cancer. 2018 Feb 15;142(4):691-701
pubmed: 28983918
Crit Rev Oncol Hematol. 2018 Feb;122:179-193
pubmed: 29458786
Acta Oncol. 2009;48(5):646-790
pubmed: 19925375
BJS Open. 2021 Jan 8;5(1):
pubmed: 33609378
Dis Esophagus. 2020 Mar 16;33(3):
pubmed: 31608927
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt E):1-538
pubmed: 23193840
Cancers (Basel). 2022 Apr 12;14(8):
pubmed: 35454845
Acta Oncol. 2010 Jun;49(5):725-36
pubmed: 20491528
Int J Cancer. 2014 Oct 15;135(8):1774-82
pubmed: 24945976
Br J Cancer. 2018 Apr;118(8):1130-1141
pubmed: 29567982
Ann Oncol. 2022 Oct;33(10):992-1004
pubmed: 35914638
Ann Surg. 2021 Nov 1;274(5):743-750
pubmed: 34353984
BMJ Open Gastroenterol. 2021 Jul;8(1):
pubmed: 34272211
PLoS One. 2022 Jan 4;17(1):e0261124
pubmed: 34982793
Ann Oncol. 2022 Oct;33(10):1005-1020
pubmed: 35914639
J Dig Dis. 2022 Jan;23(1):22-32
pubmed: 34821032
Cancer Commun (Lond). 2021 Nov;41(11):1137-1151
pubmed: 34563100
Acta Oncol. 2020 Nov;59(11):1266-1274
pubmed: 33073632